Table 1 Tumor response of different pathologic subtypes
|  | AITL | ALK unknown ALCL | ALK+ ALCL | ALK− ALCL | ENKL | PTCL others | PTCL-NOS | All |
|---|---|---|---|---|---|---|---|---|
Chidamide alone | Â | Â | Â | Â | Â | Â | Â | Â |
 ORR n (%) | 32 (49.23) | 4 (44.44) | 4 (66.67) | 3 (37.50) | 5 (15.15) | 5 (55.56) | 47 (37.30) | 100 (39.06) |
 CR n (%) | 6 (9.23) | 1 (11.11) | 4 (66.67) | 2 (25.00) | 2 (6.06) | 1 (11.11) | 11 (8.73) | 27 (10.55) |
 PR n (%) | 26 (40.00) | 3 (33.33) | 0 (0.00) | 1 (12.50) | 3 (9.09) | 4 (44.44) | 36 (28.57) | 73 (28.52) |
 DCR n (%) | 49 (75.38) | 6 (66.67) | 5 (83.33) | 6 (75.00) | 14 (42.42) | 6 (66.67) | 79 (62.70) | 165 (64.45) |
Chidamide combined with chemotherapy regimens | ||||||||
 ORR n (%) | 25 (71.43) | 1 (33.33) | 2 (100.00) | 1 (14.29) | 8 (40.00) | 3 (75.00) | 25 (44.64) | 65 (51. 18) |
 CR n (%) | 4 (11.43) | 0 (0.00) | 1 (50.00) | 0 (0.00) | 2 (10.00) | 1 (25.00) | 7 (12.50) | 15 (11.81) |
 PR n (%) | 21 (60.00) | 1 (33.33) | 1 (50.00) | 1 (14.29) | 6 (30.00) | 2 (50.00) | 18 (32.14) | 50 (39.37) |
 DCR n (%) | 31 (88.57) | 1 (33.33) | 2 (100.00) | 5 (71.43) | 10 (50.00) | 4 (100.00) | 41 (73.21) | 94 (74.02) |
Combined with CHOP-like regimens | ||||||||
 ORR n (%) | 7 (77.78) | 1 (50.00) | 0 (0.00) | 0 (0.00) | 1 (33.33) | 2 (100.00) | 6 (40.00) | 17 (53.13) |
 CR n (%) | 2 (22.22) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 1 (33.33) | 1 (50.00) | 0 (0.00) | 4 (12.50) |
 PR n (%) | 5 (55.56) | 1 (50.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 1 (50.00) | 6 (40.00) | 13 (40.63) |
 DCR n (%) | 9 (100.00) | 1 (50.00) | 0 (0.00) | 1 (100.00) | 2 (66.67) | 2 (100.00) | 11 (73.33) | 26 (81.25) |
Combined with platinum-containing regimens | ||||||||
 ORR n (%) | 9 (75.00) | 0 (0.00) | 1 (100.00) | 0 (0.00) | 3 (42.86) | 0 (0.00) | 9 (37.50) | 22 (45.83) |
 CR n (%) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 4 (16.67) | 4 (8.33) |
 PR n (%) | 9 (75.00) | 0 (0.00) | 1 (100.00) | 0 (0.00) | 3 (42.86) | 0 (0.00) | 5 (20.83) | 18 (37.50) |
 DCR n (%) | 11 (91.67) | 0 (0.00) | 1 (100.00) | 2 (66.67) | 3 (42.86) | 0 (0.00) | 15 (62.50) | 32 (66.67) |
Combined with other regimens | ||||||||
 ORR n (%) | 9 (64.29) | 0 (0.00) | 1 (100.00) | 1 (33.33) | 4 (40.00) | 1 (50.00) | 10 (58.82) | 26 (55.32) |
 CR n (%) | 2 (14.29) | 0 (0.00) | 1 (100.00) | 0 (0.00) | 1 (10.00) | 0 (0.00) | 3 (17.65) | 7 (14.89) |
 PR n (%) | 7 (50.00) | 0 (0.00) | 0 (0.00) | 1 (33.33) | 3 (30.00) | 1 (50.00) | 7 (41.18) | 19 (40.43) |
 DCR n (%) | 11 (78.57) | 0 (0.00) | 1 (100.00) | 2 (66.67) | 5 (50.00) | 2 (100.00) | 15 (88.24) | 36 (76.60) |